PASG
Passage Bio Inc
NASDAQ: PASG · HEALTHCARE · BIOTECHNOLOGY
$5.11
-4.49% today
Updated 2026-04-30
Market cap
$18.32M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-14.35
Dividend yield
—
52W range
$5 – $20
Volume
0.1M
Passage Bio Inc (PASG) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | — | $134000.00 | $800000.00 | $1.54M | $3.68M | $3.72M | $3.08M | $728000.00 |
| Gross profit | — | $-134000.00 | $-800000.00 | $-1.54M | $-3.68M | $-3.72M | $-3.08M | $-728000.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $9.17M | $30.24M | $82.79M | $117.67M | $86.05M | $59.56M | $40.18M | $23.28M |
| SG&A | $928000.00 | $6.95M | $30.11M | $60.06M | $49.34M | $41.58M | $24.99M | $19.88M |
| Operating income | $-13.47M | $-37.19M | $-112.90M | $-185.73M | $-138.39M | $-100.14M | $-70.40M | $-43.15M |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $-7.42M | $-36.55M | $-111.10M | $-176.19M | $-131.72M | $-98.34M | $-62.09M | $-42.42M |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | $-22.86M | $-36.69M | $-111.90M | $-177.73M | $-135.39M | $-102.06M | $-65.17M | $-43.15M |
| Interest expense | $696000.00 | $8.45M | $670000.00 | $343000.00 | $2.27M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-12.77M | $-45.63M | $-112.23M | $-185.39M | $-136.13M | $-102.06M | $-64.77M | $-45.52M |
| Net income growth (YoY) | — | -257.4% | -145.9% | -65.2% | +26.6% | +25.0% | +36.5% | +29.7% |
| Profit margin | — | — | — | — | — | — | — | — |